AngioDynamics (AngioDynamics) EBIT per Share

: $-1.59 (TTM As of Feb. 2024)

View and export this data going back to 2004. Start your Free Trial

AngioDynamics's EBIT per Share for the three months ended in Feb. 2024 was $-0.29. Its EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2024 was $-1.59.

During the past 3 years, the average EBIT per Share Growth Rate was -8.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for AngioDynamics's EBIT per Share or its related term are showing as below:

ANGO' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -155.5 Med: -9.6 Max: 34.8
Current: -8.5

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of AngioDynamics was 34.80% per year. The lowest was -155.50% per year. And the median was -9.60% per year.

ANGO's 3-Year EBIT Growth Rate is ranked worse than
69.88% of 727 companies
in the Medical Devices & Instruments industry
Industry Median: 7.5 vs ANGO: -8.50

AngioDynamics's EBIT for the three months ended in Feb. 2024 was $-11.6 Mil.

AngioDynamics EBIT per Share Historical Data

The historical data trend for AngioDynamics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

EBIT per Share

-0.26

-4.41

-0.92

-0.75

-1.31

AngioDynamics Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EBIT per Share																-0.14	-0.90	-0.24	-0.17	-0.29

AngioDynamics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

AngioDynamics's EBIT per Share for the fiscal year that ended in May. 2023 is calculated as

	EBIT per Share		(A: May. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-51.735	/	39.480
=	-1.31

AngioDynamics's EBIT per Share for the quarter that ended in Feb. 2024 is calculated as

	EBIT per Share		(Q: Feb. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-11.598	/	40.234
=	-0.29

EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.59

AngioDynamics (NAS:ANGO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

AngioDynamics EBIT per Share Related Terms

Thank you for viewing the detailed overview of AngioDynamics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

AngioDynamics (AngioDynamics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (NAS:ANGO) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

UG2:Germany

Address

14 Plaza Drive, Latham, NY, USA, 12110

Website

https://www.angiodynamics.com

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.

Executives

Lorinda Burgess	director	22 WEST FRONTAG ROAD, NORTHBROOK IL 60093
Karen A Licitra	director	C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael E Tarnoff	director	C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Scott Centea	officer: SVP/GM, VIT	C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Dave Helsel	officer: SVP Global Operations and R&D	400 WOOD ROAD, BRAINTREE MA 02184
Laura Piccinini	officer: SVP International	C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110
Stephen A Trowbridge	officer: SVP and General Counsel	14 PLAZA DRIVE, LATHAM NY 120110
James C Clemmer	director, officer: President and CEO	COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Wesley Johnson	director
Chad Thomas Campbell	officer: SVP/GM, Vascular Access	140 POKANOKET PATH, WRENTHAM MA 02093
Warren Jr Nighan	officer: SVP Quality and Regulatory	ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Richard C Rosenzweig	officer: SVP and General Counsel	C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kevin J Gould	director	247 WASHINGTON STREET, DUXBURY MA 02332
Brent J. Boucher	officer: SVP and GM of Oncology	14 PLAZA DRIVE, LATHAM NY 12110
Michael Greiner	officer: EVP and CFO	C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421